BioSpace News Archive

Geneva, Switzerland, November 18, 2021 - Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that CEO, Tim Dyer, and Head of Discovery – Biology, Dr Robert Lütjens, will be attending the virtual German Equity Forum to be held November 22 – 24, 2021.

Following on from the positive top line read out of Part A our Phase 3 study, we initiated a structured process to select our commercial partner for Nefecon in Europe.

Sanofi announced an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.

According to a newly released TMR report, the orthopaedic implants market will offer much to smile about for investors during 2018-2026 period.

Nordic Nanovector ASA, a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives of patients with haematological cancers, will host an R&D Day on Tuesday, 30 November 2021 starting at 14:00 CET/ 13:00 GMT/ 08:00 ET.

The global mycoplasma infections diagnostics market is consolidated to a large extent with the leading five vendors jointly accounting for 68.0 % of the global market in 2016, notes Transparency Market Research.

An increase in the prevalence of lifestyle diseases around the world and the rising geriatric population will serve as prominent reason for the growth of the human microbiome market during the forecast period of 2018-2026.

The Europe pharmaceutical market has been anticipated to grow at a significant speed in the forthcoming years.

Transparency Market Research has published a new report on the companion animal diagnostics market for the forecast period of 2019–2027.

Albany, New York, June 27th, 2020: A lucrative growth curve will be charted by global chronic kidney disease drugs market over the forecast period of 2016 to 2024.